Interview with Rajiv Chopra, President DSM India & MD DSM Nutirtional…
With almost EUR 9bn turnover and more than 22,000 people worldwide, Royal DSM has truly grown into an MNC. Within the global market, there is no doubt that India has…
Address: Corpora Building, 2d Floor, LBS Marg, Bhandup West, Mumbai 400 078 INDIA ,India
Tel: +91 22 4342 4040
Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture.
It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets. Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion (USD 2.9bn).
With almost EUR 9bn turnover and more than 22,000 people worldwide, Royal DSM has truly grown into an MNC. Within the global market, there is no doubt that India has…
Looking back at the company’s recent challenges, we see a very tough 2009, largely due to the Betapharm acquisition and the subsequent changes in German regulations. How do you explain…
Since the company’s foundation in 1993, Hetero has clearly come a long way. What were the key success factors at that time, which laid the groundwork of a successful company?…
Over the years, multinational corporations (MNCs) have increasingly been penetrating the Indian pharmaceutical markets. How have you observed this trend throughout your career? Based on India’s macro-economic growth of around…
India is clearly a new location for Cockram, and what brought you here was your loyal customer Pfizer. After 3 years of project work, a permanent business has now also…
Dilip Surana of family-run Indian generics giant Micro Labs talks company performance, the evolution of the Indian pharma market, and strategy moving forward. Last year Micro Labs moved up in…
Having been director here in India between 1998-2002, and then again since 2006, you have clearly been in the front seat to observe the evolution of the Indian market. How…
You have very successfully executed a vision that you have had for the company since it was a 200 Rs Cr turnover, India-focused enterprise 15 years ago. You have had…
When Astellas announced to expand its presence in India in 2009, you were already speaking of the company’s long commitment and solid relationship with India. Can you elaborate on these…
What probably best explains the contrasts in the Indian pharmaceutical landscape is the fact that India can take many shapes and forms and that different companies in India will keep…
For decades now, ACG has been building up its reputation in the global pharma space. The Indian Pharma industry, at the same time, increasingly is catching up with the Western…
For decades now, ACG has been building up its reputation in the global pharma space. The Indian Pharma industry, at the same time, increasingly is catching up with the Western…
See our Cookie Privacy Policy Here
